BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Wednesday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Several other brokerages also recently weighed in on BIOL. Ascendiant Capital Markets reduced their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 target price on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Price Performance

BIOLASE stock opened at $0.01 on Wednesday. The firm has a market capitalization of $167,035.00, a P/E ratio of 0.00 and a beta of 0.67. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94. The company’s 50-day moving average is $0.02 and its 200 day moving average is $0.07.

Institutional Trading of BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC grew its position in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is currently owned by institutional investors and hedge funds.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.